Shiga-like toxins (SLTs), are also called Verotoxins. Enterohemorrhagic Escherichia coli (EHEC) strains which are primarily of serotypes 0157:H7, 026:H11 and O111:H8 have been incriminated as etiologic agents of hemorrhagic colitis and Hemolytic-uremic syndrome, a generalized disease characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. There are several distinct E.coli SLTs. SLT-I and SLT-II are produced by EHEC. SLT-I and Shiga toxin share >99% deduced amino acid sequence homology, whereas SLT-I and SLT-II share about 60% deduced amino acid sequence homology. SLT-I and SLT-II are antigenically distinct. The protein structure of the toxin consists of two domains: the A polypeptide that inhibits protein synthesis by targeting ribosomes, and the B polypeptide pentamer that binds to the eukaryotic cell receptor globotriaosylceramide (Gb3) leading to receptor-mediated endocytosis.
Applications:
Suitable for use in ELISA, Western Blot and Toxin Neutralization. Other applications not tested.
Recommended Dilutions:
ELISA (Capture): 10ug/ml
ELISA (Detection): 1ug/ml
Western Blot: 1ug/ml
Toxin Neutralization (Antitoxin: Toxin): 10:1
Optimal dilutions to be determined by the researcher.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Quick Search
Products 
